Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 132

1.

Techniques and short-term outcomes for total minimally invasive Ivor Lewis esophageal resection in distal esophageal and gastroesophageal junction cancers: pooled data from six European centers.

Straatman J, van der Wielen N, Nieuwenhuijzen GA, Rosman C, Roig J, Scheepers JJ, Cuesta MA, Luyer MD, van Berge Henegouwen MI, van Workum F, Gisbertz SS, van der Peet DL.

Surg Endosc. 2016 Apr 29. [Epub ahead of print]

PMID:
27129563
2.

Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer.

Shapiro J, Biermann K, van Klaveren D, Offerhaus GJ, Ten Kate FJ, Meijer SL, van Berge Henegouwen MI, Steyerberg EW, Wijnhoven BP, Lanschot JJ.

Ann Surg. 2016 Jan 14. [Epub ahead of print]

PMID:
27115900
3.

Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery.

Shapiro J, van Klaveren D, Lagarde SM, Toxopeus EL, van der Gaast A, Hulshof MC, Wijnhoven BP, van Berge Henegouwen MI, Steyerberg EW, van Lanschot JJ.

Br J Surg. 2016 Apr 26. doi: 10.1002/bjs.10142. [Epub ahead of print]

PMID:
27115731
4.

Preoperative functional status is not associated with postoperative surgical complications in low risk patients undergoing esophagectomy.

van Egmond MA, van der Schaaf M, Klinkenbijl JH, Engelbert RH, van Berge Henegouwen MI.

Dis Esophagus. 2016 Feb 26. doi: 10.1111/dote.12469. [Epub ahead of print]

PMID:
26918788
5.

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.

Ebbing EA, Medema JP, Damhofer H, Meijer SL, Krishnadath KK, van Berge Henegouwen MI, Bijlsma MF, van Laarhoven HW.

Oncotarget. 2016 Mar 1;7(9):10243-54. doi: 10.18632/oncotarget.7200.

6.

18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making.

Anderegg MC, de Groof EJ, Gisbertz SS, Bennink RJ, Lagarde SM, Klinkenbijl JH, Dijkgraaf MG, Bergman JJ, Hulshof MC, van Laarhoven HW, van Berge Henegouwen MI.

PLoS One. 2015 Nov 3;10(11):e0133690. doi: 10.1371/journal.pone.0133690. eCollection 2015.

7.

Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.

Spierings LE, Lagarde SM, van Oijen MG, Gisbertz SS, Wilmink JW, Hulshof MC, Meijer SL, Anderegg MC, van Berge Henegouwen MI, van Laarhoven HW.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S766-71. doi: 10.1245/s10434-015-4850-3. Epub 2015 Sep 8.

PMID:
26350367
8.

A Quantified Scoring System for Postoperative Complication Severity Compared to the Clavien-Dindo Classification.

Slaman AE, Lagarde SM, Gisbertz SS, van Berge Henegouwen MI.

Dig Surg. 2015;32(5):361-6. doi: 10.1159/000433608. Epub 2015 Aug 7.

PMID:
26279268
9.

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, Ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group.

Lancet Oncol. 2015 Sep;16(9):1090-8. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.

PMID:
26254683
10.
11.

Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial).

Haverkamp L, Brenkman HJ, Seesing MF, Gisbertz SS, van Berge Henegouwen MI, Luyer MD, Nieuwenhuijzen GA, Wijnhoven BP, van Lanschot JJ, de Steur WO, Hartgrink HH, Stoot JH, Hulsewé KW, Spillenaar Bilgen EJ, Rütter JE, Kouwenhoven EA, van Det MJ, van der Peet DL, Daams F, Draaisma WA, Broeders IA, van Stel HF, Lacle MM, Ruurda JP, van Hillegersberg R; LOGICA study group.

BMC Cancer. 2015 Jul 29;15:556. doi: 10.1186/s12885-015-1551-z.

12.

Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease - interim results of an international multicentre trial.

Kappelle WF, Bredenoord AJ, Conchillo JM, Ruurda JP, Bouvy ND, van Berge Henegouwen MI, Chiu PW, Booth M, Hani A, Reddy DN, Bogte A, Smout AJ, Wu JC, Escalona A, Valdovinos MA, Torres-Villalobos G, Siersema PD.

Aliment Pharmacol Ther. 2015 Sep;42(5):614-25. doi: 10.1111/apt.13306. Epub 2015 Jul 8.

PMID:
26153531
13.

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.

Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ; SANO study group.

JMIR Res Protoc. 2015 Jun 29;4(2):e79. doi: 10.2196/resprot.4320.

14.

Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma.

van Nistelrooij AM, van der Korput HA, Broer L, van Marion R, van Berge Henegouwen MI, van Noesel CJ, Biermann K, Spaander MC, Tilanus HW, van Lanschot JJ, Hofman A, Uitterlinden AG, Wijnhoven BP, Dinjens WN.

J Carcinog. 2015 May 21;14:5. doi: 10.4103/1477-3163.157441. eCollection 2015.

15.

Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer.

Klaassen R, Bennink RJ, van Tienhoven G, Bijlsma MF, Besselink MG, van Berge Henegouwen MI, Wilmink JW, Nederveen AJ, Windhorst AD, Hulshof MC, van Laarhoven HW.

Radiother Oncol. 2015 Jul;116(1):94-9. doi: 10.1016/j.radonc.2015.05.009. Epub 2015 Jun 3.

PMID:
26049919
16.

Quality of Life and Late Complications After Minimally Invasive Compared to Open Esophagectomy: Results of a Randomized Trial.

Maas KW, Cuesta MA, van Berge Henegouwen MI, Roig J, Bonavina L, Rosman C, Gisbertz SS, Biere SS, van der Peet DL, Klinkenbijl JH, Hollmann MW, de Lange ES, Bonjer HJ.

World J Surg. 2015 Aug;39(8):1986-93. doi: 10.1007/s00268-015-3100-y.

17.

Endoscopic closure of acute perforations of the GI tract: a systematic review of the literature.

Verlaan T, Voermans RP, van Berge Henegouwen MI, Bemelman WA, Fockens P.

Gastrointest Endosc. 2015 Oct;82(4):618-28.e5. doi: 10.1016/j.gie.2015.03.1977. Epub 2015 May 21. Review.

PMID:
26005015
18.

Endoscopy/EUS-guided fiducial marker placement in patients with esophageal cancer: a comparative analysis of 3 types of markers.

Machiels M, van Hooft J, Jin P, van Berge Henegouwen MI, van Laarhoven HM, Alderliesten T, Hulshof MC.

Gastrointest Endosc. 2015 Oct;82(4):641-9. doi: 10.1016/j.gie.2015.03.1972. Epub 2015 May 7.

PMID:
25957478
19.

Burden of spousal caregivers of stage II and III esophageal cancer survivors 3 years after treatment with curative intent.

Haj Mohammad N, Walter AW, van Oijen MG, Hulshof MC, Bergman JJ, Anderegg MC, van Berge Henegouwen MI, Henselmans I, Sprangers MA, van Laarhoven HW.

Support Care Cancer. 2015 Dec;23(12):3589-98. doi: 10.1007/s00520-015-2727-4. Epub 2015 Apr 18.

20.

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract.

Damhofer H, Ebbing EA, Steins A, Welling L, Tol JA, Krishnadath KK, van Leusden T, van de Vijver MJ, Besselink MG, Busch OR, van Berge Henegouwen MI, van Delden O, Meijer SL, Dijk F, Medema JP, van Laarhoven HW, Bijlsma MF.

J Transl Med. 2015 Apr 11;13:115. doi: 10.1186/s12967-015-0469-1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk